GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » EV-to-EBITDA
中文

Biomark Diagnostics (Biomark Diagnostics) EV-to-EBITDA : -27.58 (As of Apr. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biomark Diagnostics's enterprise value is $21.46 Mil. Biomark Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.78 Mil. Therefore, Biomark Diagnostics's EV-to-EBITDA for today is -27.58.

The historical rank and industry rank for Biomark Diagnostics's EV-to-EBITDA or its related term are showing as below:

BMKDF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.56   Med: -12.96   Max: -6.04
Current: -27.58

During the past 10 years, the highest EV-to-EBITDA of Biomark Diagnostics was -6.04. The lowest was -32.56. And the median was -12.96.

BMKDF's EV-to-EBITDA is ranked worse than
100% of 118 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.53 vs BMKDF: -27.58

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Biomark Diagnostics's stock price is $0.2249. Biomark Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.045. Therefore, Biomark Diagnostics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biomark Diagnostics EV-to-EBITDA Historical Data

The historical data trend for Biomark Diagnostics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics EV-to-EBITDA Chart

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.30 -10.34 -29.27 -15.18 -13.55

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.41 -13.55 -19.66 -24.29 -22.83

Competitive Comparison of Biomark Diagnostics's EV-to-EBITDA

For the Diagnostics & Research subindustry, Biomark Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's EV-to-EBITDA falls into.



Biomark Diagnostics EV-to-EBITDA Calculation

Biomark Diagnostics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=21.458/-0.778
=-27.58

Biomark Diagnostics's current Enterprise Value is $21.46 Mil.
Biomark Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomark Diagnostics  (OTCPK:BMKDF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biomark Diagnostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.2249/-0.045
=At Loss

Biomark Diagnostics's share price for today is $0.2249.
Biomark Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.045.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biomark Diagnostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines